Sun Acquisitions

AUGUST 5, 2024

In the dynamic world of mergers and acquisitions (M&A), staying ahead of the curve is crucial for success. From the increasing prevalence of cross-border transactions to the transformative impact of technology, let’s delve into some of the latest trends shaping the future of M&A.

M&A 59

M&A Mergers and Acquisitions IPO Valuation 59

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 30, 2024

As we look ahead to the 2024 proxy season (and beyond), let’s review the key 2023 trends and developments from activism playbooks, with a sharp focus on the ever-changing landscape in the technology and healthcare sectors. Momentum building for 2024? 4] Activists won 134 board seats globally in 2023, a 30% increase from 2022.

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 25, 2023

Tech M&A in 2022 was a tale of two halves. 2] Despite the downtrend, global tech M&A activity in 2022 remained strong relative to pre-pandemic levels and accounted for a record 20% of all global M&A activity. Deal volumes dropped from $531.13 billion [1] during the first half of 2022 to $189.17 trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

Fortunately, for those with the ever common resolution to slim down, the life sciences sector offers inspiration. Unlike in 2023, when a Q4 dealmaking binge over the holidays led to the sector outperforming the market, life sciences M&A cut down and stuck with it throughout 2024. Luckily, theres more to this years story.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

MergersCorp M&A International

MAY 27, 2025

Special Purpose Acquisition Companies (SPACs), once hailed as the “blank check” path to public markets, have experienced a rollercoaster ride over the past few years. This acquisition, known as a “de-SPAC” transaction, effectively takes the private company public without undergoing the traditional IPO process.

IPO 52

IPO Mergers and Acquisitions Investors Capital 52